Harry Erba, MD, PhD

Harry P. Erba, MD, PhD, is a professor of medicine in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine at the Duke University School of Medicine, as well as director of the Leukemia Program and director of Phase I Development in Hematologic Malignancies. He is also a member of the Duke Cancer Institute

Articles

FDA Approval Insights: Ziftomenib in NPM1+ R/R AML: With Harry P. Erba, MD, PhD

November 21st 2025

Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.

The Role of Genetic Profiling in Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.

Goals in the Treatment of Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.

Factors When Weighing Intensive Chemotherapy vs Other Regimens in Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.

Dose Intensity and Sequencing of Intensive Chemotherapy in Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.

Long-Term Data for CPX-351 in Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.

Defining Intensive Chemotherapy Fitness in AML

October 24th 2024

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.

The Diagnosis and Prevalence of Secondary AML

October 24th 2024

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.

Dr Erba on the Safety of Quizartinib By Treatment Phase and Age in FLT3-ITD–positive AML

June 25th 2024

Harry Erba, MD, PhD, discusses the safety profile of quizartinib according to treatment phase and age in newly diagnosed patients with FLT3-ITD–positive acute myeloid leukemia.

Experts Highlight Their Biggest Takeaways from the 2023 SOHO Annual Meeting

September 25th 2023

Key opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.

Dr Erba on the Role of Quizartinib in Newly Diagnosed FLT3-ITD+ AML

September 9th 2023

Harry Erba, MD, PhD, discusses the role of quizartinib for the treatment of newly diagnosed patients with FLT3-ITD–positive acute myeloid leukemia.

Dr Erba on the FDA Approval of Quizartinib Plus Chemotherapy in FLT3-ITD–Positive AML

July 20th 2023

Harry P. Erba, MD, PhD, discusses the significance of the FDA approval of quizartinib in combination with chemotherapy in patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

Dr Erba on the Initial Safety and Activity of Ziftomenib in AML

July 10th 2023

Harry P Erba, MD, PhD, discusses the safety profile and preliminary activity of the investigational menin inhibitor ziftomenib in acute myeloid leukemia.

Acute Myeloid Leukemia: Updates From The ASH 2022 Annual Meeting

February 14th 2023

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

ASH 2022: Recent Advances in Chronic Myeloid Leukemia

February 14th 2023

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

ASH 2022: Updates in the Acute Lymphocytic Leukemia Treatment Landscape

February 14th 2023

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

December 21st 2022

Harry Erba, MD, PhD shares an update from the recent ASH 2022 Annual Meeting on a phase 1/2 trial of the menin-KMT2A (MLL) Inhibitor ziftomenib in patients with relapsed or refractory acute myeloid leukemia.

Examining Headway in AML and Multiple Myeloma at ASH 2022: Drs Braunstein and Erba

December 11th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Dr. Erba on Selecting Between Ibrutinib and Acalabrutinib in CLL

October 18th 2021

Harry Paul Erba, MD, PhD, discusses selecting between ibrutinib and acalabrutinib in chronic lymphocytic leukemia.

Dr. Erba on the Evolution of Treatment in MCL

October 14th 2021

Harry Paul Erba, MD, PhD, discusses the evolution of treatment in mantle cell lymphoma.